Booster shots for COVID-19 may be available by fall


The CEO of US-based pharmaceutical and biotechnology company Moderna said he wants a booster shot for the double-dose COVID-19 vaccine to be available in the fall.

Stephane Bancel interview At CNBC’s Squawk Box on Wednesday, the company said it was working on booster shots. CCP (Chinese Communist Party) virus— This causes the disease COVID-19.

“I think we’ll see a lot of varieties next year or so,” Bansel said. “But as more and more people are vaccinated or infected naturally, the pace of the variants slows down and the virus stabilizes, as seen in influenza.”

“I would like to make sure there is a boost vaccine available in the fall to protect people as they enter the next fall and winter seasons in the United States,” he said.

Moderna is developing a new vaccine booster and plans to make it available by next year, but according to internal data from a small laboratory study, the company still protects the current vaccine against some new variants. Said to provide (pdf) Between Moderna and the National Institute of Allergy and Infectious Diseases (NIAID).

To New research A Phase 3 study, released Tuesday by a Massachusetts-based company, found that the current COVID-19 vaccine is more than 90% effective in all cases of the virus and more than 95% in severe cases of the virus. He said it shows that it is valid. 6 months from the second shot.

A study published in the New England Journal of Medicine suggests that protection from the Moderna vaccine lasts for at least 6 months. To date, Moderna has been vaccinated with the COVID-19 vaccine approximately 132 million times worldwide.

Vaccine box
Boxes containing the Moderna COVID-19 vaccine are ready to be shipped to the Macqueson Distribution Center in Olive Branch, Mississippi, on December 20, 2020. (Paul Sancya / AP photo, pool)

COVID-19 was caused by a CCP virus, commonly referred to as the coronavirus, and occurred in China in late 2019.

In the study, Bansel said a team of scientists would advance clinical data from “variant-specific booster candidates” as soon as possible and keep updating the results.

“We look forward to obtaining clinical data from mutant-specific booster candidates and from Phase 2/3 trials of the COVID-19 vaccine in adolescence,” said Bansel. ..

“New preclinical data on our mutant-specific vaccine candidates gives us confidence that we can actively work on new mutants,” he continued. “Moderna will update the COVID-19 vaccine as much as needed until the pandemic is controlled.”

Earlier this year, the company announced that it was developing a new vaccine to be used as a third shot or booster to combat more infectious variants of the CCP virus, including the first variant detected in South Africa. did.

To date, B.1.1.7 is the predominant in the United States, with 20,915 cases reported. by Centers for Disease Control and Prevention (CDC).

Bansel also said Wednesday’s COVID-19 would never “leave the planet,” reiterating his belief that annual booster vaccines would become commonplace in the future.

From NTD News

Posted on